Stewart Spies

Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20⁺B-Cell Non-Hodgkin's Lymphoma

Thomas E. Witzig, Christine A. White, Gregory A. Wiseman et al. · Journal of Clinical Oncology · 1999 · 538 citations

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial

Gregory A. Wiseman, Leo I. Gordon, Pratik S. Multani et al. · Blood · 2002 · 266 citations · Full text

Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

Gregory A. Wiseman, Christine A. White, Michael Stabin et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2000 · 234 citations

Lymphoid Neoplasia, Radioimmunotherapy Dosimetry Results, Phase I/ii 90 +7

Left ventricular function during and after right ventricular pacing

Maher Nahlawi, Michael Waligora, Stewart Spies et al. · Journal of the American College of Cardiology · 2004 · 224 citations

Cardiac Muscle, Heart Failure, Cardiac Mechanic +6

Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.

Gregory A. Wiseman, Ellen Kornmehl, Bryan R. Leigh et al. · PubMed · 2003 · 216 citations